Glucagon-like peptide-1 (GLP-1) receptor agonists — including Ozempic (semaglutide), Wegovy (semaglutide), Mounjaro (tirzepatide) and Zepbound (tirzepatide) — have revolutionised diabetes and obesity treatment.
However, as their use has surged, so have self-reported mood changes — including anxiety, depression, emotional blunting and even suicidal thoughts within weeks of starting the drugs, as discussed in the psychiatrist’s video above.
Why Some People Are Reporting Psychiatric Symptoms
In the video, a board-certified psychiatrist and former FDA medical officer explains that:
This does not conclusively prove causation — but it emphasises that clinical trials may not capture every meaningful real-world experience.
What Clinical & Regulatory Reports Say
📌 Official Regulatory Position
Major regulators, including the U.S. FDA, have reviewed available evidence and concluded that:
At the same time, agencies like Australia’s Therapeutic Goods Administration (TGA) and others have updated product labels and warnings to highlight reports of mood changes and suicidal ideation, stressing vigilance and reporting of symptoms.
📊 Observational Data & Emerging Signals
Some research suggests statistically elevated risks of psychiatric outcomes with GLP-1 use in large patient databases — including increased risks of depression, anxiety and suicidal behaviour — though causal links are not clearly established.
Other analyses find no increased risk in controlled settings.
Possible Mechanisms Being Investigated
Experts believe several factors could contribute:
🧠 Direct Neurochemical Effects
GLP-1 receptors exist in brain areas regulating reward, mood and appetite. Altering their signalling may affect:
🧠 Indirect Psychological Effects
Changes in eating behaviour, rapid weight loss and metabolic shifts may:
These factors may confound psychiatric symptoms — but can still be real and distressing for users.
🍽️ Nutrition & Metabolism
Very low food intake — often seen when appetite is suppressed — is known to affect mood and can:
Even without direct drug effects, these changes can contribute to depressive symptoms.
What Patients Are Reporting (Anecdotal Experience)
Many people online and in clinical settings describe:
✔ Sudden onset of anxiety or depressive symptoms
✔ Emotional blunting or reduced joy
✔ Loss of motivation or personality changes
✔ Improvement upon stopping the medication
Case reports and anecdotal evidence do not prove causation, but they can highlight signals that warrant further study — especially when patterns are consistent across multiple reports.
What the Science Community Says
There is no definitive consensus yet:
This means the medical community is still gathering evidence and cautious monitoring remains prudent.
Clinical & Safety Takeaways
If you are taking a GLP-1 medication and notice:
🟡 Persistent sadness or mood changes
🟡 Increased anxiety
🟡 Emotional dulling or personality changes
🟡 Suicidal thoughts
Speak with your healthcare provider immediately.
Do not stop medication abruptly without medical guidance.
Mood changes may be related to:
All of these warrant professional evaluation.
Final Thoughts
Key points to consider:
Meet Malcolm Today!
Founder and General Manager of UltraLite Progam
Join UltraLite Today!
For 26 years, UltraLite’s healthy ketogenic program has changed lives. Join the success stories—or step up and help others succeed as an UltraLite practitioner.